Comparison of patients with successful and unsuccessful treatment switch
| Patients with successful treatment change (n = 9) | Patients with unsuccessful treatment change (n = 7) | P** | |
|---|---|---|---|
| Age at diabetes diagnosis, months | 178 (1; 262) | 120 (1; 159) | 0.203 |
| Duration of diabetes until treatment change, months | 54 (16; 267) | 221 (30; 336) | 0.031 |
| Age at treatment change, months | 264 (17; 313) | 321 (160; 347) | 0.023 |
| HbA1c before treatment change, % [mmol/mol] | 6.8 (5.5; 11.6) [51 (37; 103)] | 8.7 (7.3; 13.1) [72 (56; 120)] | 0.080 |
| HbA1c after treatment change, % [mmol/mol] | 6.4 (5.6; 10.2) [46 (38; 88)] | 11.6 (7.6; 12.8) [103 (60; 116)] | 0.011 |
| C-peptide before treatment change, pmol/L# | 498 (220; 1,140) | 65 (1; 252) | 0.005 |
| Insulin treatment, n (%) | 8 (89) | 7 (100) | 1$ |
| Insulin dose before treatment change, units/kg/day | 0.5 (0.2; 1.3) | 0.9 (0.6; 1.1) | 0.117 |
Data are median (minimum; maximum) unless otherwise indicated. Summary of the 16 patients who were offered treatment switch after genetic diagnosis. Nine patients (six with HNF1A and three with KCNJ11 diabetes) could successfully be treated with sulfonylureas. Seven patients (three with HNF4A, two with ABCC8, one with HNF1A, and one with KCNJ11 diabetes) had to restart insulin therapy.
*Mann-Whitney U test.
$Fisher exact test.
#One missing value in both groups.